Amber Therapeutics
Carmela C. is an experienced professional in clinical operations and research, currently serving as Head of US Clinical Operations at Amber Therapeutics since October 2024. Prior to this role, Carmela C. worked as a consultant at Avania from January 2023 to October 2024 and held the position of VP, Clinical Affairs (US) at Occlutech from 2021 to November 2022. Additional experience includes roles as Clinical Program Manager at Abiomed and Terumo Medical Corporation, and Clinical Subjects Coordinator at the University of Michigan Health System. Carmela C. began a career in the field with positions at PDL BioPharma, I. Brodsky Associates, Theravance Biopharma US, Inc., and the Office of Statewide Health Planning and Development. Educational qualifications include a Master of Science degree from Drexel University College of Medicine and a Bachelor of Science degree from the University of California, Davis.
This person is not in any teams
This person is not in any offices
Amber Therapeutics
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, medtech industry professionals and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The Company is backed by Oxford Science Enterprises and 8VC.